Study on the Safety of High Dose Administration of Astaxanthin
|
Accession number;05A0586948
|
| Title;Study on the Safety of High Dose Administration of Astaxanthin |
| Author;
OGAMI KAZUHIRO
(Hokkaido Univ., Graduate School of Medicine, JPN)
SHIRATORI KENJI
(Hokkaido Univ., Graduate School of Medicine, JPN)
NITTA TAKUYA
(Hokkaido Univ., Graduate School of Medicine, JPN)
SHINMEI YASUHIRO
(Hokkaido Univ., Graduate School of Medicine, JPN)
CHIN SHINKI
(Hokkaido Univ., Graduate School of Medicine, JPN)
YOSHIDA KAZUHIKO
(Hokkaido Univ., Graduate School of Medicine, JPN)
TSUKAHARA HIROKI
(Fuji Chem. Ind. Co., Ltd.)
ONO SHIGEAKI
(Hokkaido Univ., Graduate School of Medicine, JPN)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.21;NO.6;PAGE.651-659(2005)
|
| Figure&Table&Reference;FIG.2, TBL.7, REF.11 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Ten healthy volunteers were given 2 soft capsules of Astaxanthin, each containing 15mg of Astaxanthin derived from H. pluvialis, everyday for 4 weeks and the safety of high dose administration of Astaxanthin was studied. The subjects were requested to visit the outpatient clinic of ophthalmology of Hokkaido University, before administration of Astaxanthin, at the end of 2nd and 4th week after administration, and at the end of 2nd and 4th week after stopping administration for their hematological, biochemical and urine tests. In addition, physical and ophthalmological examinations were also done. Concurrently, adverse events and compliance were checked in interview by doctors. In consequence, no clinically meaningful abnormal changes were noted in either of examinations and no adverse events due to Astaxanthin were found, therefore high dose of H. pluvialis Astaxanthin (daily dose of 30mg) was considered to be safe. (author abst.) |
|
|
|
Related Articles;
|
|
